Workflow
创业板医药ETF国泰(159377)涨2.17%,医药生物行业估值与持仓处历史低位

Group 1 - The core viewpoint of the news highlights the positive movement in the pharmaceutical sector, particularly with the rise of the ChiNext Pharmaceutical ETF and the implications of new regulatory policies [1] - The "Medical Device Network Sales Quality Management Specification" was released on May 9, outlining responsibilities and quality management requirements for online sales operators and e-commerce platforms [1] - On May 20, 2023, 3SBio announced an exclusive licensing agreement with Pfizer for its self-developed PD-1/VEGF bispecific antibody SSGJ-707, which includes an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion [1] Group 2 - Huayuan Securities noted that the pharmaceutical and biotechnology industry is showing multiple bottom characteristics, with policy impacts gradually adjusting and valuations at historical lows [2] - The innovation sector is gaining momentum, with companies like Heng Rui Medicine and Hansoh Pharmaceutical completing their innovation transformations and significantly increasing R&D investments post-2020 [2] - The aging population is accelerating the demand for chronic disease management, positioning the silver economy as a long-term growth opportunity [2]